menu
    • menu

    Company profile for Artios Pharma Limited

    NEW Drugs in Dev: 4
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Artios Pharma Ltd was established in May 2016 to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy. Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This is what causes cancers to overcome many current therapies. Targeting the remaining DDR pathways has been proven to selectively kill cancer cells through a conc...
    Artios Pharma Ltd was established in May 2016 to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy. Cancers change their DDR pathways to allow mutations in their DNA so that they can evolve and adapt. This is what causes cancers to overcome many current therapies. Targeting the remaining DDR pathways has been proven to selectively kill cancer cells through a concept known as ‘synthetic lethality’. This has been demonstrated with the recent success of PARP inhibitors such as Lynparza™ (olaparib; AstraZeneca) in treating a number of cancer types.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Artios Pharma Limitedunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Meditrina (B260) Babraham Research Campus Cambridge CB22 3AT
    Telephone
    Telephone
    +44 (0)1223 804180
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.artiospharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/artios-pharma-ltd
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/artiospharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Artios' Phase 2A Study: Alnodesertib Combo Hits Primary Endpoint
    Artios' Phase 2A Study: Alnodesertib Combo Hits Primary Endpoint

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247293/0/en/Artios-Reports-Randomized-Phase-2a-Study-of-Low-Dose-Alnodesertib-Plus-Gemcitabine-Achieves-Primary-Endpoint-in-Platinum-Resistant-Ovarian-Cancer.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    FDA Fast-Tracks Artios' ART6043 for gBRCA+ HER2- Breast Cancer
    FDA Fast-Tracks Artios' ART6043 for gBRCA+ HER2- Breast Cancer

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242542/0/en/Artios-Receives-U-S-FDA-Fast-Track-Designation-for-DNA-Polymerase-Theta-Pol%CE%B8-Inhibitor-ART6043-for-Treatment-of-gBRCA-mutated-HER2-Negative-Breast-Cancer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Artios Strengthens Leadership Team To Accelerate Late-Stage
    Artios Strengthens Leadership Team To Accelerate Late-Stage

    16 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/16/3238682/0/en/Artios-Strengthens-Leadership-Team-to-Accelerate-Late-Stage-Development-of-Potential-First-in-Class-Oncology-Pipeline.html

    GLOBENEWSWIRE
    16 Feb 2026
    Share Share
    Artios To Present At J.P. Morgan Healthcare Conference
    Artios To Present At J.P. Morgan Healthcare Conference

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214472/0/en/Artios-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Artios Secures $115M Series D To Advance Clinical Programs
    Artios Secures $115M Series D To Advance Clinical Programs

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189084/0/en/Artios-Announces-Oversubscribed-115-Million-Series-D-Financing-to-Accelerate-Clinical-Programs-in-Indications-of-High-Unmet-Need.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Artios Unveils ART6043 Phase 1/2A Data At ESMO Congress 2025
    Artios Unveils ART6043 Phase 1/2A Data At ESMO Congress 2025

    17 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/17/3168732/0/en/Artios-Announces-Phase-1-2a-Data-for-DNA-Polymerase-Theta-Inhibitor-ART6043-at-ESMO-Congress-2025.html

    GLOBENEWSWIRE
    17 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search